Literature DB >> 22480625

Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option?

Seethalakshmi Ramanathan1, Jaak Panksepp, Brian Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22480625     DOI： 10.1016/j.psym.2011.11.006

Source DB:  PubMed          Journal:  Psychosomatics        ISSN： 0033-3182            Impact factor:   2.386


× No keyword cloud information.
  6 in total

Review 1.  Intermittent blockade of OGFr and treatment of autoimmune disorders.

Authors:  Ian S Zagon; Patricia J McLaughlin
Journal:  Exp Biol Med (Maywood)       Date:  2018-12-12

2.  Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and β-Endorphin.

Authors:  Marissa J Metz; Caitlin M Daimon; Shane T Hentges
Journal:  eNeuro       Date:  2021-06-16

3.  The Neuropsychoanalytic Approach: Using Neuroscience as the Basic Science of Psychoanalysis.

Authors:  Brian Johnson; Daniela Flores Mosri
Journal:  Front Psychol       Date:  2016-10-13

4.  Low dose Naltrexone for induction of remission in inflammatory bowel disease patients.

Authors:  Mitchell R K L Lie; Janine van der Giessen; Gwenny M Fuhler; Alison de Lima; Maikel P Peppelenbosch; Cokkie van der Ent; C Janneke van der Woude
Journal:  J Transl Med       Date:  2018-03-09       Impact factor: 5.531

5.  The Effects of Low Dose Naltrexone on Opioid Induced Hyperalgesia and Fibromyalgia.

Authors:  Daniel Jackson; Sunita Singh; Yanli Zhang-James; Stephen Faraone; Brian Johnson
Journal:  Front Psychiatry       Date:  2021-02-16       Impact factor: 4.157

6.  Depression in Fibromyalgia Patients May Require Low-Dose Naltrexone to Respond: A Case Report.

Authors:  Jagoda Siembida; Brian Johnson
Journal:  Cureus       Date:  2022-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.